Heart Conditions in Pregnancy

Why this is taken so seriously

ACOG Practice Bulletin No. 212 states the position bluntly. In the United States, cardiovascular disease "is now the leading cause of death in pregnant women and women in the postpartum period", "accounting for 4.23 deaths per 100,000 live births, a rate almost twice that of the United Kingdom", and cardiovascular diseases constitute "26.5% of U.S. pregnancy-related deaths".

Those figures deserve reading carefully. The 4.23 per 100,000 live births is a US population rate, and ACOG itself notes it is roughly double the UK rate. The 26.5% is a share of pregnancy-related deaths in the US, not a risk to you. What these numbers actually tell you is why cardiac disease in pregnancy gets consultant-led, multidisciplinary, written-in-advance care: not because your individual risk is high, but because when things go wrong in this group they go wrong quickly.

ACOG also names the contributing factors it wants fixed, including "barriers to prepregnancy cardiovascular disease assessment", "missed opportunities to identify cardiovascular disease risk factors during prenatal care" and "delays in recognition of cardiovascular disease symptoms during the puerperium". Every one of those is a system failure rather than a patient failure, which is worth knowing if you have been made to feel you are making a fuss.

The modified WHO classification decides almost everything

NICE guideline NG121 organises intrapartum care for heart disease around the modified WHO classification, which grades pregnancy risk from class 1 through class 4 according to the specific cardiac lesion. You should know your class, because it drives the plan.

For modified WHO class 3 and class 4 heart disease, NG121 recommendation 1.3.37 says to offer intrapartum monitoring of the heart and circulation, which "will usually include continuous invasive intra-arterial pressure monitoring and may include central venous pressure monitoring and advanced cardiac output monitoring". Recommendation 1.3.35 says to consider collaborative working between an obstetric anaesthetist and a cardiac anaesthetist for those classes.

Recommendation 1.3.38 is the one most relevant to how your labour will feel: offer low-dose regional analgesia to women with modified WHO class 3 or 4 heart disease "because this is less likely to cause cardiac instability during labour and birth". An epidural in this setting is a cardiac intervention, not a comfort measure.

Fluid balance, and the conditions where it is critical

NG121 recommendation 1.3.20 asks teams to identify women with heart disease "for whom fluid balance is critical to cardiac function", and names severe left-sided stenotic lesions such as aortic stenosis and mitral stenosis among them. Recommendation 1.3.21 then sets out the monitoring for that group: hourly monitoring of fluid input and output with at least four-hourly assessment by a senior clinician, plus blood pressure, pulse, respiratory rate and oxygen saturation, escalating to continuous intra-arterial blood pressure monitoring and cardiac output monitoring or serial echocardiography where needed. NICE adds that women needing intensive monitoring should be told it may have to happen in an intensive care unit.

That is not a sign something has gone wrong. It is the plan working.

Drugs avoided around birth

NG121 names ergometrine as a drug to avoid in specific cardiac contexts "because of risk of hypertension-induced aortic dissection or rupture". Ergometrine is used for the third stage of labour and for postpartum haemorrhage, so this needs to be recorded in your notes rather than remembered in an emergency. The guideline also flags limited or fixed low cardiac output, preload-dependent circulation, and severe systemic ventricular dysfunction with an ejection fraction below 30% as situations changing what is safe.

Your usual cardiac medicines are reviewed before or in early pregnancy. Several classes of blood pressure and heart failure medicine are changed in pregnancy, and anticoagulation for mechanical valves is one of the most complex decisions in obstetric medicine. This page names none of them with a dose, because those decisions belong to a joint cardiac and obstetric team.

Symptoms not to dismiss

NG121 recommendation 1.3.24 asks clinicians to take a cardiac-specific history and to suspect heart failure if there is no other likely cause for symptoms including "breathlessness when lying down (ruling out aortocaval compression) or at rest". Pregnancy causes breathlessness, palpitations and ankle swelling in almost everyone, which is precisely why these features get missed.

The pattern that should trigger assessment rather than reassurance is breathlessness at rest or when lying flat, waking at night breathless, chest pain, fainting rather than feeling faint, or a resting heart rate that is persistently high for you. These matter as much in the six weeks after birth as during pregnancy, and ACOG explicitly names delayed recognition in the puerperium as a problem.

Planning, and the appointment to ask for

The single most useful thing is a preconception cardiology review, because it is the only point at which the question "should this valve or this arrhythmia be treated first" can still be answered. If you are already pregnant, ask for joint cardiac and obstetric review early rather than at the point symptoms appear.

Alongside cardiac planning, NICE guideline NG201 sets the routine antenatal schedule everyone receives, NICE guideline NG133 covers blood pressure problems that may develop on top of your cardiac condition, and RCOG's patient information on venous thrombosis explains why clot risk assessment is done in pregnancy and repeated after birth, which is relevant because many cardiac conditions raise it. The NHS pages on congenital heart disease are a reasonable place to start if your condition was diagnosed in childhood and you have not thought about it in years.